New ultrasound test for quickly identifying hyperfibrinolysis
Official title: A Novel Viscoelastic Test Based on Ultrasonic Guided Wave for Identifying Hyperfibrinolysis Rapidly
Run by Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT06374953 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new ultrasound method to quickly find out if patients have hyperfibrinolysis during surgery by using small blood samples.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06374953 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults scheduled for general surgery who require routine thromboelastography (TEG) measurement.
✕Probably not a fit
Patients with significant coagulation and fibrinolysis abnormalities or those on medications affecting coagulation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational pilot study evaluates a novel ultrasound-based viscoelastic hemostasis analysis method for detecting hyperfibrinolysis in patients undergoing surgery. By comparing this new approach to existing fibrinolysis monitoring technologies, the study aims to assess its analytical performance using small blood samples collected during routine procedures. The method utilizes ultrasound guided waves to analyze the dynamic changes in blood properties during coagulation and clot lysis, making it suitable for use in operating theatres and emergency rooms.
Why it matters
Potential benefit: If successful, this test could provide rapid and accurate identification of hyperfibrinolysis, improving patient outcomes in surgical settings.
How similar studies have gone: While this approach is novel, similar studies have shown promise in improving coagulation monitoring techniques.
Who can join: the full rules
Show full inclusion / exclusion criteria
PART 1 Inclusion Criteria: Subject is scheduled for surgery with general surgery Subject is 18 years or order Subject requires routine TEG measurement Exclusion Criteria: Subject with coagulation and fibrinolysis exceeding normal values based on laboratory tests (including prothrombin time, international normalized ratio, activated partial thromboplastin time, plasma fibrinogen concentration, D-dimer, platelet count, hemoglobin concentration, and hematocrit) Subject with any abnormal parameters detected by TEG Subject with a history of bleeding and thrombosis Subject who has taken any medications that may affect coagulation, platelet aggregation, or fibrinolysis within the past 10 days (including non-steroidal anti-inflammatory drugs and aspirin) Residual blood volume \<1ml PART 2 Inclusion Criteria: Subject is scheduled for surgery with general surgery Subject is 18 years or order Subject Subjects with detected hyperfibrinolysis (LY30\>8%) or non-hyperfibrinolysis(LY30≤8%) based on TEG. Exclusion Criteria: Residual blood volume \<1ml
Where it's running
-
The Second Affiliated Hospital of Zhejiang University anesthesiology department
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Fengjiang ZHANG
- Email: zrzfj@zju.eud.cn
- Phone: +8613858007629
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.